Benaroya Research Institute leads the Immune Tolerance Network (ITN), a collaborative network for clinical research, funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH).
Immune tolerance therapies reprogram the immune system so that disease-causing immune responses are stopped while maintaining the immune system’s ability to combat pathogen infection. The ITN develops and conducts clinical trials, each supported by mechanistic studies, of specialized immune tolerance therapies in the following areas:
- Autoimmune Disease
- Allergies and Asthma
- Organ Transplantation
In 2021 BRI was awarded its second seven year grant of $27 million annually to provide management and oversight of the Network and fund the ITN’s development, coordination, and implementation of international clinical trials for novel therapies and mechanistic, laboratory-based studies in immune tolerance. The ITN grant is one of the largest NIH awards made to any institution and is a significant recognition of the stature of BRI in the research community.
The ITN is also a leading innovator in clinical transparency, as well as data and sample sharing through TrialShare, an online resource that provides access to underlying data, analyses and samples from ITN’s clinical trials. The TrialShare web portal addresses a critical gap in data sharing, making information from research studies fully available so that results can be verified and extended.
ITN Leadership at BRI
BRI Staff Supporting ITN
Shannon Achilles
Alison Bemis
Xin Chen
Olivia Doyle, PhD
Jesse Forrest
Aaron Gannon
Jared Hennessey
Andrew Kastner
Kidan Kebede
Michael Konieczny
Nabil Morad
Blanca Obregon
Sebastian Ramos
Ben Siyum
Learn more about ITN
Progress Against Peanut Allergies
One question inspired Erik Wambre, PhD, to dedicate his career to allergy research. “Why can most people eat peanuts without a problem, but some people have a serious reaction to just a small amount?” he says. “What makes one person allergic and not another?”
Hope for MS Powers Support for BRI
Debra Smith first learned about BRI when a friend invited her to the Boeing Classic Golf Tournament in the early 2010s. BRI’s work became personal when she was diagnosed with multiple sclerosis (MS) in 2013.
Volunteering in a COVID-19 Vaccine Trial: BRI Team Members Share Their Experience
Without clinical research participants, we might not have groundbreaking cancer treatments like immunotherapy or vaccines for polio, rubella and other life-threatening diseases.